{"links":{"html":"https://www.erudio.com/reports/tritons-nct06587490","json":"https://www.erudio.com/reports/tritons-nct06587490.json","markdown":"https://www.erudio.com/reports/tritons-nct06587490.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"tritons-06587490"}},"request":"https://www.erudio.com/contact?report=tritons-06587490"},"offer":{"cited_commentary_sources":7,"verified_hcp_statements":38,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":12,"optional":true,"price_per_verified_person_usd":15,"price_usd":180,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"tritons-nct06587490"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=tritons-06587490","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/tritons-nct06587490","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T02:00:56.591604Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":0,"title":"Secondary endpoint: All-grade and grade ≥3 toxicity"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":1,"title":"Biological spectrum, disease pace and the interpretation of ablation trials"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":2,"title":"Prostate imaging, lesion definition and response assessment"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":1,"title":"De novo oligometastatic hormone-sensitive prostate cancer: progression-pattern rationale for MDT"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":1,"title":"Colorectal-surgery biomarker scope, access and disclosure"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Single-fraction SBRT as an optimization question"},{"claim_count":2,"coverage":"discussed","id":"A6","source_count":1,"title":"Randomized secondary analyses and net clinical benefit"}],"counts":{"cited_sources":8,"claims_by_expression_type":{"comparison":3,"experience":1,"interpretation":11,"opinion":10,"primary_context":1,"question":3,"restatement":7,"uncertainty":2},"claims_by_kind":{"protocol_statement":1,"source_observation":37},"clinician_statements":28,"evidence_units":51,"findings":6,"organisational_accounts":2,"people_cited":12,"people_identity_verified":12,"people_total":12,"screened_sources":22,"verified_claims":38},"findings_index":[{"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":2,"views":7},"has_counterview":true,"limitations":2,"links":{"context":2,"support":15},"ma_question":true,"named_voices":4,"passages":13,"sources":2,"sources_by_kind":{"commentary":1,"registry":1}},"title":"Technical ablatability is not an agreed biological definition of oligometastasis"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":6,"passages":9,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Prostate progression patterns support a proposed mechanism, not proof of added MDT benefit"},{"id":"F3","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Prostate response assessment is a specific methodological concern"},{"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":2},"has_counterview":true,"limitations":3,"links":{"context":3,"support":7},"ma_question":true,"named_voices":4,"passages":8,"sources":4,"sources_by_kind":{"commentary":3,"registry":1}},"title":"The upper treatment burden and safe extent of ablation remain open questions"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":3,"passages":7,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Interest in biomarker selection is practical, but the discussed test has a colorectal-surgery scope"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":7,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"Optimism is accompanied by calls for randomization, enrollment and benefit-based selection"}],"medical_affairs_question":"Which baseline biology, disease pace, systemic-treatment context and imaging approach identify patients likely to gain net benefit from adding SABR?","sections":{"analysis":[{"id":"section-1","level":3,"title":"Biological selection is not the same as technical treatability"},{"id":"section-2","level":3,"title":"Prostate progression patterns provide a rationale with competing explanations"},{"id":"section-3","level":3,"title":"Imaging uncertainty affects both lesion definition and response assessment"},{"id":"section-4","level":3,"title":"Greater treatment extent requires a benefit–harm answer"},{"id":"section-5","level":3,"title":"Biomarker interest is broader than the demonstrated scope of the discussed test"},{"id":"section-6","level":3,"title":"Trial optimism remains tied to learning who benefits"},{"id":"section-7","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[],"id":"T2","label":"Secondary endpoint: All-grade and grade ≥3 toxicity"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":5}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T02:00:56.591604Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T02:11:52Z","record_hash":"62988c7d0a8e74e54710c16cfe16440609368cbcdf0ca6b2b3f4b112e5390007","release_hash":"e49dc75a9fb02675f7a3095743ed081a60fb84a0aab74f3051fd05eb7c090258","report_id":"erudio-nct06587490","run_id":"7f34da99-69d0-47aa-90fb-9328fa7874f0","schema_version":"5.0","slug":"tritons-06587490","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"TRITONS asks whether adding stereotactic ablative radiotherapy to standard care improves outcomes in oligometastatic solid cancers. One X poster contests technical ablatability as a biological definition of oligometastasis. A speaker, described in the source as a principal investigator of TRITONS, expresses optimism about ablation alongside calls for randomized evidence; an X poster relays uncertainty about safe treatment extent. Which patients benefit, and how disease control balances against treatment harm, remain open questions.","meta_description":"22 sources screened · 38 verified statements (28 from clinicians verified by NPI or staff page) from 8 sources · 6 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-6563eff738f724ad90f1","claim-32131b92c7881a66c127"],"id":"F4","paraphrase":"An X thread reporting a talk addresses how extensively metastatic sites can be treated safely in the oligometastatic setting studied by TRITONS.","publication_caveats":["The safety statement is relayed from a talk rather than a direct account by its presenter.","Interpretations of a separate trial elsewhere in this finding are not TRITONS results.","The sources reviewed for this edition provide neither TRITONS toxicity rates nor an established optimal fractionation schedule."],"source_channel":"x_thread","source_date":"2026-04-16","title":"The upper treatment burden and safe extent of ablation remain open questions"},{"cited_claim_ids":["claim-60a1fa9690145d4b970a"],"id":"F3","paraphrase":"An X post raises the question of which imaging response criteria to use for prostate metastases in TRITONS.","publication_caveats":["The principal-investigator involvement is described by the source, not independently confirmed.","The comments concern prostate cancer and should not be generalized to every tumor type in TRITONS.","The sources reviewed for this edition do not describe a validated replacement assessment framework or document a change to TRITONS assessment methods."],"source_channel":"x_thread","source_date":"2025-10-06","title":"Prostate response assessment is a specific methodological concern"}]},"publication":{"approved_at":"2026-10-30T02:11:52Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":22},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","The source search did not run to completion, so some matching discussion may be missing.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are selected public discussions, not a representative survey. Some relevant passages were not fully assessed, and unnamed or differently worded references to the trial may be missing.","No TRITONS efficacy or toxicity results are provided. The October 2026 publication discussion concerns a protocol announcement and linked article information, not a results report or a complete protocol assessment.","Several discussions concern separate settings, including de novo oligometastatic hormone-sensitive prostate cancer, oligoprogressive disease and colorectal-cancer surgery. Their interpretations cannot be treated as TRITONS outcomes or validated selection rules for its entire population.","A speaker's statements about the talk are relays rather than a direct transcript of its presenter. Another speaker's principal-investigator involvement is described by the source and should not be treated as an independently established role or an external appraisal.","Reposts and relays do not establish additional independent HCP agreement. The nature of a speaker's disclosed interest in the prognostic test remains unclear."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":7,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":7,"methods":1},"count":8,"evidence_window":{"end":"2026-10-23","start":"2025-07-03"},"retrieval_snapshot":"2026-10-30T01:24:40.447302Z","timeline":[{"count":1,"week":"2025-W27"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W16"},{"count":2,"week":"2026-W17"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06587490:methods","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-khuv74dp3olqgnga7b4wv32v-3lkhpvwpqcs2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-khuv74dp3olqgnga7b4wv32v-3lklwxamxys2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-l424hzotgxywad7cey6udedu-3lkhrfhmzck2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-l424hzotgxywad7cey6udedu-3lkjhvryvys2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-l424hzotgxywad7cey6udedu-3mwh2k2fmsl2t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-srnkqtcpptdtesojmwbgoek2-3lk4jmn7lrk2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-srnkqtcpptdtesojmwbgoek2-3lkubemj5ac2s","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834066555837317140:3a73c6ba-f6c6-46e7-a149-620235f88c58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1901531786964070454:9d942009-59a7-4999-a8d1-5c4b0dff062b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1910696789738742033:4cb8dae2-0d76-468b-8e16-1bfbe2971b52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1917571850173047112:cffbc15b-1335-4f0f-b246-f2b484e4b51a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940758726346195002:f7edccd1-6d92-4f66-9ffb-dbad33704b21","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1975281851863605271:93be9282-507c-4ef7-989d-b1cfd7561d6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1999142049766093171:6cdc9fc4-2833-4c3b-98d2-da8a5251e780","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2044904216733356433:d07bee4c-9e23-4aeb-909c-02ab32ec9c0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046682961311842566:3e841faa-2008-4008-b37a-4390cfd14517","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049880210946900326:6c427c54-74c1-4ae0-baca-9980ea573dd9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050194871168684370:337c4454-8586-42cc-83f8-bd3833d8d8b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097674604089385167:50b865a6-5098-450f-8c36-f1e9cbd8c1b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104777849702060338:42c7f517-3ba4-4452-990c-36d6adc265d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113299435153207526:52989b5d-3bae-48f4-9e6d-a2b0ea2836b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113444454795460932:34d6aa8c-93a7-4be9-b55a-f6f9581c2f14","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":7,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":22},"count":22,"evidence_window":{"end":"2026-10-23","start":"2024-09-12"},"retrieval_snapshot":"2026-10-30T01:24:40.447302Z","timeline":[{"count":1,"week":"2024-W37"},{"count":3,"week":"2025-W11"},{"count":4,"week":"2025-W12"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W27"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W16"},{"count":2,"week":"2026-W17"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"reason":"Unmapped registry condition: Oligometastatic Malignant Solid Neoplasm","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"TRITONS","aliases":["TRITONS","Total RadIoTherapy of Oligometastatic caNcerS","Total RadIoTherapy of Oligometastatic caNcerS (TRITONS)"],"brief_title":"Total RadIoTherapy of Oligometastatic caNcerS","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Oligometastatic Malignant Solid Neoplasm"],"display_condition":"oligometastatic cancer","display_interventions":[],"enrollment":{"count":300,"type":"ESTIMATED"},"interventions":[{"name":"stereotactic ablative radiotherapy","synonyms":["SABR"],"type":"RADIATION"}],"nct_id":"NCT06587490","official_title":"Total RadIoTherapy of Oligometastatic caNcerS (TRITONS)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2033-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"Rate of Progression Free Survival in the two study arms","measure":"Progression-Free Survival (PFS)","timeFrame":"2 years"}],"registered_date":{"date":"2024-09-19","type":"ACTUAL"},"registry_last_updated":"2026-10-16","registry_url":"https://clinicaltrials.gov/study/NCT06587490","short_name":"TRITONS","short_name_basis":"registry_acronym","sponsor":"University of California, San Diego","start_date":{"date":"2024-11-12","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"810616","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}